Spain-based Almirall has named Peter Guenter as its new chief executive officer, it was reported yesterday.
The new chief executive officer is to succeed Eduardo Sanchiz, who leaves to dedicate more time to other interests.
Guenter joins from Sanofi, where he has worked for the past 22 years, most recently as executive vice president diabetes and cardiovascular global business unit. He earlier held various senior positions at Sanofi, including vice president Eastern Europe and Northern Europe, vice president business management and support, general manager, Germany, and senior vice president, Europe.
Sanchiz will hand over the Almirall leadership to Guenter during September.
Esperion to acquire Corstasis, expanding cardiovascular portfolio
Circio reports up to 50-fold gene expression gain in eye for circVec-AAV platform
Celyad Oncology sells C-Cathez catheter to CellProthera
Realheart secures European patent for artificial heart technology
Cumberland Pharmaceuticals secures FDA Fast Track status for DMD heart‑disease therapy ifetroban
Myqorzo and Redemplo receive regulatory approval in China
Kestra partners with Biobeat to add cuffless blood pressure monitoring to wearable defibrillator
Organon signs commercialisation agreement for Nilemdo across six European markets